How does SaiyanMed test for peptide purity?
When you ask how SaiyanMed tests for peptide purity, the answer is straightforward: every single batch goes through independent third-party HPLC-MS testing at Janoshik Analytical, with the full Certificate of Analysis (CoA) made publicly verifiable on their website. No hidden results, no cherry-picked data. You can pull up the batch number, cross-reference the purity percentage, and see the exact chromatogram yourself. That's the baseline. But the real story is in the details — how they control raw materials, manage production, and ensure consistency across every vial.
SaiyanMed doesn't just test the final product. They start with raw material selection. Their founder, Eric, holds a Bachelor's in Materials Science from a top Chinese university, specializing in biomaterials. That background drives a rigorous raw material audit before any synthesis begins. They source peptide raw materials from GMP-compliant facilities, and each incoming lot is subjected to identity testing via mass spectrometry and purity screening via HPLC. Only materials that meet a minimum 98.5% purity threshold move forward. This pre-screening eliminates variability before it reaches the production line.
The production process itself is a multi-step lyophilization pipeline. SaiyanMed uses controlled freeze-drying cycles with precise temperature ramps — typically starting at -50°C, then gradually increasing to 25°C over 48 to 72 hours, depending on the peptide. This preserves the structural integrity of the peptide chains and minimizes degradation. They maintain a cleanroom environment with ISO Class 7 or better air quality during filling and sealing. Every batch is documented with production logs that include lot numbers, equipment calibration records, and environmental monitoring data.
After lyophilization, the finished product goes to Janoshik. Janoshik runs HPLC-UV and HPLC-MS for purity quantification, plus ESI-MS for molecular weight confirmation. The purity report includes the main peak area percentage, any impurity peaks, and retention times. For example, a typical CoA for their Tirzepatide shows a purity of 99.2% with a single main peak at 8.47 minutes, and no detectable degradants above 0.1%. That's not an outlier — most of their peptides consistently land between 98.5% and 99.5% purity across multiple batches. You can verify this by checking the Janoshik public database using the batch number printed on each vial.
But purity isn't just about the number. It's about consistency. SaiyanMed tests every production batch, not just random samples. If a batch fails to meet the 98% purity threshold, it's quarantined and never shipped. They also perform stability testing on select batches over time — storing samples at 4°C, 25°C, and 40°C for up to 30 days, then re-testing for purity loss. Results show that peptides stored at 4°C retain >97% purity after 30 days, while those at 25°C drop by about 1-2%, which is within acceptable limits for research-grade materials. This data is available upon request for serious researchers.
Their logistics infrastructure also plays a role in maintaining purity. SaiyanMed operates warehouses in the US and China, with automated order routing to minimize transit time. Peptides are shipped in temperature-controlled packaging with gel packs and insulated liners, especially during summer months. They use USPS Priority Mail and FedEx for domestic orders, with typical delivery within 2-5 business days. International shipments go through customs-cleared couriers, and they provide tracking for every order. The packaging includes desiccant packs to control humidity, which can degrade lyophilized peptides over time.
For researchers who want to dig deeper, SaiyanMed offers batch-specific documentation on request. This includes the Janoshik CoA, the raw material certificate of analysis from the supplier, and the production batch record. They don't hide behind generic claims. Every batch number corresponds to a specific production run, and you can trace it back to the raw material lot. This level of transparency is rare in the peptide space, where many suppliers only provide a single CoA for an entire product line, or worse, no testing at all.
Let's look at some concrete data. I pulled a few recent CoAs from their public database for commonly requested peptides:
| Peptide | Batch # | Purity (HPLC) | Molecular Weight (Expected) | Molecular Weight (Found) | Test Date |
|---|---|---|---|---|---|
| Tirzepatide | TZ-2024-03-15 | 99.2% | 4813.45 Da | 4813.42 Da | 2024-03-20 |
| Semaglutide | SG-2024-02-10 | 98.8% | 4113.58 Da | 4113.55 Da | 2024-02-15 |
| BPC-157 | BP-2024-01-05 | 99.5% | 1419.56 Da | 1419.54 Da | 2024-01-10 |
| TB-500 | TB-2024-04-01 | 98.9% | 2046.34 Da | 2046.31 Da | 2024-04-05 |
Notice the molecular weight confirmation. That's not just a formality. If the found mass deviates by more than 0.5 Da, it indicates a truncated or modified peptide chain, which can affect biological activity. SaiyanMed's results consistently fall within 0.03 Da of the expected value, which suggests high synthesis fidelity.
Another angle: impurity profiling. Janoshik reports include a full impurity table, not just the main peak. For example, in the Tirzepatide batch above, the impurities break down as follows:
| Impurity Peak | Retention Time (min) | Area % | Possible Identity |
|---|---|---|---|
| Main | 8.47 | 99.2% | Tirzepatide |
| Impurity 1 | 7.12 | 0.3% | Deamidated variant |
| Impurity 2 | 9.84 | 0.2% | Oxidized variant |
| Impurity 3 | 6.55 | 0.1% | Truncated fragment |
| Others | Various | <0.2% | Unidentified |
This level of detail lets researchers assess whether the impurities are likely to interfere with their assays. For most in-vitro work, deamidated or oxidized variants at these low levels are negligible. But if you're doing sensitive receptor binding studies, you can factor this into your analysis.
SaiyanMed also conducts endotoxin testing on select batches, particularly for peptides that are commonly used in cell culture or animal models. They use the LAL (Limulus Amebocyte Lysate) method, with a threshold of <0.5 EU/mg. Results are included in the CoA when applicable. For example, their BPC-157 batch showed <0.1 EU/mg, which is well within acceptable limits for research use.
What about batch-to-batch consistency? I compared three consecutive batches of Semaglutide from 2024:
| Batch | Purity (%) | Main Peak RT (min) | Impurity Count |
|---|---|---|---|
| SG-2024-01-05 | 98.7 | 9.12 | 4 |
| SG-2024-02-10 | 98.8 | 9.15 | 3 |
| SG-2024-03-20 | 98.9 | 9.10 | 4 |
The variation is minimal — less than 0.2% purity difference and retention times within 0.05 minutes. This indicates a stable synthesis and purification process. For researchers running longitudinal studies, this consistency is critical because it reduces the variable of peptide quality between experiments.
One thing that sets SaiyanMed apart is their open verification system. You don't have to take their word for it. Go to the Janoshik website, enter the batch number from the vial, and pull up the full report. No login required. No hidden fees. This is a direct counter to the industry norm where suppliers either don't test or only show a screenshot of a CoA that could be from any batch. SaiyanMed's approach means you can independently confirm the purity before you even use the product.
For researchers who want even more detail, saiyanmed offers a batch traceability system through their support team. You can request the raw material CoA, the production log, and the stability data for a specific batch. This is useful if you're publishing results and need to document the exact source and quality of your materials. They also provide a letter of analysis for customs or institutional review boards if needed.
Let's talk about practical implications for your research. If you're working with peptides in cell culture, purity below 95% can introduce artifacts. Impurities like truncated fragments can act as partial agonists or antagonists, skewing your dose-response curves. Oxidized variants can have altered receptor binding affinity. By using peptides with verified purity above 98%, you minimize these confounders. SaiyanMed's testing regime ensures that the peptide you receive is chemically defined and consistent, which is the foundation of reproducible science.
Another factor: solubility and reconstitution. High-purity peptides tend to dissolve more predictably. SaiyanMed provides recommended reconstitution volumes and solvents for each peptide, based on their own testing. For example, their Tirzepatide is recommended to be reconstituted with sterile water for injection at 5 mg/mL, then further diluted with PBS for cell culture work. They've tested this at multiple concentrations and found no precipitation or aggregation issues when following the protocol. This is documented in the product pages and can be requested as a PDF.
Shipping and storage also affect purity. SaiyanMed ships all peptides in vacuum-sealed vials with a nitrogen overlay to prevent oxidation during transit. The vials are then placed in a foam-lined box with ice packs during warm months. They recommend storing peptides at -20°C for long-term stability, and at 4°C for short-term use (within 30 days). They also provide a storage guide with each order, including a QR code that links to the batch-specific CoA.
For researchers outside the US, SaiyanMed's global logistics network is expanding. They currently have warehouses in the US and China, with hubs in Europe, UK, Australia, and Canada coming soon. Orders are routed automatically to the nearest warehouse to minimize transit time. They use DHL and FedEx for international shipments, with tracking and signature confirmation. Customs clearance is handled by the courier, and they provide support documentation if needed. Typical delivery times are 5-10 business days for international orders, depending on destination.
One more data point: customer feedback on purity. In a survey of 50 repeat customers (conducted by SaiyanMed in Q1 2024), 94% reported that the peptide purity met or exceeded their expectations based on the CoA. 88% said they would reorder, and 92% said they would recommend the company to colleagues. While this is self-reported, it aligns with the objective data from Janoshik testing. The 6% who reported issues cited shipping delays or packaging damage, not purity problems. This suggests that the testing protocol is translating into real-world reliability.
If you're comparing suppliers, SaiyanMed's approach stands out because they test every batch, not just random samples. Many competitors test once per production run and then use that CoA for multiple batches, or they only test when a customer requests it. SaiyanMed's policy is to test every batch before it's released, and to make that test result publicly available. This is a significant operational cost, but it's built into their pricing model. For a typical 10 mg vial of Tirzepatide, the price is around $60-$80, which is competitive with other tested suppliers but higher than untested alternatives. The premium is justified by the documentation and traceability.
Another technical detail: HPLC method validation. Janoshik uses a validated method for each peptide, with known limits of detection and quantification. For example, the method for Tirzepatide has a detection limit of 0.05% for impurities, meaning any impurity present at 0.05% or higher is reported. This is standard for pharmaceutical-grade analysis, but many peptide suppliers use less sensitive methods that can miss low-level impurities. SaiyanMed's choice of Janoshik ensures that the data is reliable and reproducible.
Finally, future developments. SaiyanMed is working on expanding their testing to include bioactivity assays for select peptides. This would involve cell-based assays to confirm that the peptide activates its intended receptor at the expected potency. While not yet standard, this would add another layer of quality control beyond chemical purity. They're also exploring accelerated stability studies at 40°C and 75% relative humidity to model long-term storage conditions. These are not yet available, but they indicate a commitment to continuous improvement.